FTL and cancer: Hence, regulating pathways involved in CDKN2A-associated genes or designing novel metal-based anticancer agents to induce ferroptosis and cuproptosis may guide us to develop new anti-cancer treatment strategies for BRCA, especially for the patients in the FTL-dominant subtype.